Infant

National Survey Shows Most Mothers and Caregivers of Infants in U.S. Believe Breast Milk is Healthiest Option, but Need to Use Formula at Some Point in the First Year

Retrieved on: 
Thursday, April 4, 2024
Mother, Health, Employment, Breast milk, POS, Lactation, AAPI, Caregiver, Special, Black, Milk, Infant, Neil Newhouse, WIC, State, GQR, Government, Work, Birth control

WASHINGTON, April 4, 2024 /PRNewswire/ -- The bipartisan team of GQR and Public Opinion Strategies (POS) released results from a national survey conducted on behalf of the Infant Nutrition Council of America that examines how mothers and caregivers across demographic and racial groups choose to feed their infants and the factors that influence those decisions[1]. The survey was conducted among 1,500 mothers and caregivers in the U.S. with children less than 12 months of age.

Key Points: 
  • The survey was conducted among 1,500 mothers and caregivers in the U.S. with children less than 12 months of age.
  • But even mothers who breastfeed report barriers and lack of support from employees including time and space to pump.
  • Additionally, the survey asked mothers and caregivers of young children 12-24 months of age about their feeding concerns.
  • The vast majority of mothers and caregivers want access to information about nutritious feeding options for their toddlers (12-24 months).

CPSC Warns Consumers to Immediately Stop Using OmvedTherapies Baby Pillows Due to Suffocation Hazard; Violation of the Federal Ban on Infant Pillows

Retrieved on: 
Thursday, April 4, 2024
Parent, Infant, Seed, Sleep, Face, Human, CPSC, Caregiver, Linens

WASHINGTON, April 4, 2024 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is warning consumers to immediately stop using the OmvedTherapies infant pillows because they pose a suffocation hazard to infants.

Key Points: 
  • WASHINGTON, April 4, 2024 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is warning consumers to immediately stop using the OmvedTherapies infant pillows because they pose a suffocation hazard to infants.
  • The pillows violate the infant pillow ban because of their flexible fabric covering, loose filling, and ability to easily flatten and conform to an infant's body or face.
  • Ltd., of India, but the firm has refused to recall these infant pillows or offer a remedy to consumers.
  • CPSC urges consumers to stop using the infant pillows immediately, separate the pillowcase and pillow, and dispose of the pillowcase and pillow, as well as the lavender and mustard seed contents.

Infinant Health Announces Submission of Orphan Drug Designation Application

Retrieved on: 
Tuesday, April 2, 2024
ODD, Bifidobacterium longum, Health, Disease, Incidence, Partnership, Risk, Necrotizing enterocolitis, Health maintenance organization, Biomarker, Disorder, Milk, Mortality, Bacteria, Infant, Death, United, NEC, Mucus, Marketing, FDA, Food, Pharmaceutical industry

DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.

Key Points: 
  • DAVIS, Calif., April 2, 2024 /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health, one baby at a time, announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
  • The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
  • Orphan Drug Designation would qualify INF108 for certain benefits and incentives, including seven years of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.
  • The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

Spence Law Firm LLC: Family Alleges Gas Poisoning in Airbnb Vacation Home

Retrieved on: 
Monday, April 1, 2024
Headache, Poisoning, Risk, District court, SAN, Smell, Brain, Child, Infant, Carbon, Nausea, Vomiting, MediaWorks, Family, Carbon monoxide

SAN FRANCISCO and SANTA FE, N.M., April 1, 2024 /PRNewswire/ -- A Montana family of four alleges in new lawsuits that they were poisoned by a boiler spewing carbon monoxide gas into an Airbnb vacation rental home in Santa Fe, N.M., The Spence Law Firm and co-counsel said today.

Key Points: 
  • SAN FRANCISCO and SANTA FE, N.M., April 1, 2024 /PRNewswire/ -- A Montana family of four alleges in new lawsuits that they were poisoned by a boiler spewing carbon monoxide gas into an Airbnb vacation rental home in Santa Fe, N.M., The Spence Law Firm and co-counsel said today.
  • Tyson E. Logan , of The Spence Law Firm, said, "This is an urgent issue.
  • The poisoning did permanent and irreversible damage to this family, especially the youngest child – it will affect them forever.
  • Contact: Erin Powers, Powers MediaWorks LLC, for The Spence Law Firm, LLC, 281.703.6000, [email protected] .

Key Proteo Submits De Novo Application to FDA for its First Newborn Screening Kit

Retrieved on: 
Friday, March 29, 2024
Disease, WD, XLA, Infant, Patient, Classification, Mortality, Wiskott–Aldrich syndrome, RUO, IVD, Trial of the century, Proteomics, X-linked agammaglobulinemia, WAS, Hypogammaglobulinemia, FDA, DSM-IV codes, Food, Pharmaceutical industry

SEATTLE, March 29, 2024 /PRNewswire/ -- Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug Administration (FDA) for its first in vitro diagnostic Key Proteo Newborn Screening Kit. The novel proteomics-based screening panel addresses a critical, unmet need to aid in the early identification of four treatable rare genetic disorders that current newborn screening programs do not typically test for, including Wilson Disease (WD), Wiskott-Aldrich Syndrome (WAS), X-linked Agammaglobulinemia (XLA) and Adenosine Deaminase Deficiency (ADA). Early screening has the potential to enable timely intervention that can help change the clinical trajectory and relieve the burden of disease for patients and their families afflicted by these potentially devastating disorders.

Key Points: 
  • The submission of Key Proteo's Newborn Screening Kit 1 comes after screening over 22,000 newborn samples in an ongoing pilot study in Washington state.
  • Subsequently, Key Proteo successfully completed a clinical study that included 3,294 newborn samples analyzed at 3 sites across North America.
  • The in vitro diagnostic Key Proteo Newborn Screening Kit 1 will only be available for commercialization once the FDA has completed its process.
  • Currently, Key Proteo Newborn Screening Kit 1 is available as an RUO offering.

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
Thursday, March 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

Ready. Set. Food! and ObvioHealth Launch Innovative Trial to Correlate Infant Food Allergy Prevention with Reduced Healthcare Costs

Retrieved on: 
Thursday, March 28, 2024
Food, Pediatrics, Parent, Risk, Allergy, Infant, Insurance, Trial of the century, Health, Food allergy, Caregiver, Multimedia, Allergen

NEW YORK, March 28, 2024 /PRNewswire/ -- Ready. Set. Food! announces the launch of a pioneering clinical study (EASE trial) with ObvioHealth, which will use real-world infant healthcare data to assess how the convenient and early introduction of common food allergens impacts infant allergies and associated healthcare costs.     

Key Points: 
  • Food!
  • Food!
  • announces the launch of a pioneering clinical study (EASE trial) with ObvioHealth , which will use real-world infant healthcare data to assess how the convenient and early introduction of common food allergens impacts infant allergies and associated healthcare costs.
  • Food!

Access to Nutrition Initiative study reveals that Food for infants and toddlers from leading brands fails to meet marketing and nutritional standards

Retrieved on: 
Tuesday, March 26, 2024
Mother, Health, Caregiver, Danone, Social media, Policy, Substitute, BMS, FHA insured loan, Infant, Code, Intake, Marketing, Hero, Safety, Access, WHO, Helen Keller International, ATNI, Parent, Dietary supplement

UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.

Key Points: 
  • UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.
  • None of the commercial complementary food products for infants and young children were found suitable for promotion for consumption by children aged 6 months to three years.
  • The first study shows only 35% meet all nutritional requirements, with 25-33% of products assessed containing excessive levels of sugar or inappropriate energy levels.
  • said Kathy Spahn, Board Member of the Access to Nutrition Initiative (ATNI) and former President and CEO, Helen Keller International.

Access to Nutrition Initiative study reveals that Food for infants and toddlers from leading brands fails to meet marketing and nutritional standards

Retrieved on: 
Tuesday, March 26, 2024
Mother, Health, Caregiver, Danone, Social media, Policy, Substitute, BMS, FHA insured loan, Infant, Code, Intake, Marketing, Hero, Safety, Access, WHO, Helen Keller International, ATNI, Parent, Dietary supplement

UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.

Key Points: 
  • UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.
  • None of the commercial complementary food products for infants and young children were found suitable for promotion for consumption by children aged 6 months to three years.
  • The first study shows only 35% meet all nutritional requirements, with 25-33% of products assessed containing excessive levels of sugar or inappropriate energy levels.
  • said Kathy Spahn, Board Member of the Access to Nutrition Initiative (ATNI) and former President and CEO, Helen Keller International.